Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

• Published in: The Lancet (British edition) Vol. 372; no. 9633; pp. 117 - 126
• Main Authors: Eggermont, Alexander MM, Prof, Suciu, Stefan, PhD, Santinami, Mario, MD, Testori, Alessandro, MD, Kruit, Wim HJ, MD, Marsden, Jeremy, MD, Punt, Cornelis JA, Prof, Salès, François, MD, Gore, Martin, Prof, MacKie, Rona, Prof, Kusic, Zvonko, Prof, Dummer, Reinhard, Prof, Hauschild, Axel, Prof, Musat, Elena, MD, Spatz, Alain, MD, Keilholz, Ulrich, Prof
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 12.07.2008; Elsevier Limited; Elsevier
• Subjects: Adolescent; Adult; Aged; Antiviral Agents; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Autoimmune diseases; Cancer; Cardiovascular disease; Chemotherapy, Adjuvant; Clinical trials; Disease-Free Survival; Drug therapy; Female; Hepatotoxicity; Humans; Immunization; Interferon Alfa-2b; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Internal Medicine; Life Sciences; Male; Medical research; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Melanoma - surgery; Middle Aged; Neoplasm Metastasis; Observation; Oncology; Physical examinations; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Skin cancer; Survival; Tomography
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(08)61033-8

Summary Background Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability. Methods 1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627) 6 μg/kg per week for 8 weeks (induction) then 3 μg/kg per week (maintenance) for an intended duration of 5 years. Randomisation was stratified for microscopic (N1) versus macroscopic (N2) nodal involvement, number of positive nodes, ulceration and tumour thickness, sex, and centre. Randomisation was done with a minimisation technique. The primary endpoint was recurrence-free survival. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov , number NCT00006249. Findings All randomised patients were included in the primary efficacy analysis. 608 patients in the interferon group and 613 patients in the observation group were included in safety analyses. The median length of treatment with pegylated interferon alfa-2b was 12 (IQR 3·8–33·4) months. At 3·8 (3·2–4·2) years median follow-up, 328 recurrence events had occurred in the interferon group compared with 368 in the observation group (hazard ratio 0·82, 95% CI 0·71–0·96; p=0·01); the 4-year rate of recurrence-free survival was 45·6% (SE 2·2) in the interferon group and 38·9% (2·2) in the observation group. There was no difference in overall survival between the groups. Grade 3 adverse events occurred in 246 (40%) patients in the interferon group and 60 (10%) in the observation group; grade 4 adverse events occurred in 32 (5%) patients in the interferon group and 14 (2%) in the observation group. In the interferon group, the most common grade 3 or 4 adverse events were fatigue (97 patients, 16%), hepatotoxicity (66, 11%), and depression (39, 6%). Treatment with pegylated interferon alfa-2b was discontinued because of toxicity in 191 (31%) patients. Interpretation Adjuvant pegylated interferon alfa-2b for stage III melanoma has a significant, sustained effect on recurrence-free survival. Funding Schering Plough Research International.